Accelerating pharmaceutical manufacturing digitalization with low-code development

Pharmaceutical companies face immense pressures in terms of time, quality and compliance to stay competitive. However, traditional MES deployment timelines often span 8 to 24 months, hindering responsiveness and innovation. Opcenter Execution Pharma, now empowered by Mendix low-code platform, offers a solution to accelerate the path from concept to compliance, enabling faster innovation and smarter collaboration without compromising regulatory integrity.

How to overcome hurdles in pharma digitalization

Pharmaceutical manufacturers don't just need digitalization - they need speed. The path to digital transformation is often riddled with unique challenges, such as lengthy validation processes due to stringent regulatory requirements, collecting tribal knowledge and misalignment between central IT teams and site operations regarding efficiency expectations. These obstacles can result in missed market opportunities, increased operational risks and diminished return on investment (ROI).

Opcenter Execution Pharma, now enhanced with Mendix low-code capabilities, tackles these challenges head-on. By enabling rapid prototyping and iterative design before formal validation begins, pharmaceutical manufacturers can align stakeholders, capture tribal knowledge and ensure user buy-in early in the process. This approach significantly reduces rework, deployment time and resource strain, as changes can be made and tested before the validation process starts, minimizing the impact of late-stage change requests and ensuring a smoother, more efficient digitalization journey.

Reduce deployment risk and deliver value faster

Mendix low-code platform provides pharmaceutical manufacturers with the tools to innovate confidently, align stakeholders quickly, reduce deployment risk and deliver value faster. With reusable pharma-compliant components, pre-built connectors and a unified development environment, Opcenter Execution Pharma with Mendix capabilities empowers teams to design better, faster and more collaboratively before validation starts. This approach ensures scalable solution design without compromising compliance or increasing validation overhead, allowing pharmaceutical manufacturers to stay agile in an industry where change is constant, but compliance is non-negotiable.

Download the white paper to learn more.